United Therapeutics Corporation has moved nebulized Tyvaso into formal FDA review for idiopathic pulmonary fibrosis after the agency accepted the company’s supplemental New Drug Application. The FDA review is expected to be completed in late April 2027, and approval would make nebulized treprostinil the first inhaled treatment specifically approved for IPF, according to United Therapeutics. Tyvaso is already marketed for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, but it remains investigational for IPF itself.
The application is supported by the Phase 3 TETON-1 and TETON-2 trials, which produced a consistent lung-function signal across geographically separate patient populations. In the combined analysis, patients receiving Tyvaso had an estimated 111.8 mL advantage over placebo in absolute forced vital capacity at week 52, with a 95% confidence interval of 79.7 to 144.0 mL and a p-value below 0.0001. Several important secondary endpoints also favored treatment, including risk of clinical worsening and acute IPF exacerbation.
Why is forced vital capacity so important in idiopathic pulmonary fibrosis?
Idiopathic pulmonary fibrosis causes progressive scarring that stiffens lung tissue and gradually reduces the amount of air patients can move. Forced vital capacity measures the volume of air that a person can forcibly exhale after taking a full breath and is one of the principal clinical measures used to track progression in IPF. Falling FVC generally indicates worsening pulmonary function, although the relationship between a particular milliliter change and how an individual patient feels can vary.
In the combined TETON population, median FVC fell by 45.4 mL in the Tyvaso group compared with 161.7 mL under placebo at 52 weeks. The treatment therefore did not cause lung capacity to increase dramatically in the average patient; rather, it substantially slowed the rate at which capacity was being lost. That distinction is important because IPF remains a progressive fibrotic disease and successful therapy is often measured by preservation rather than restoration of already scarred lung tissue.
What happened in the two separate TETON Phase 3 studies?
TETON-1 enrolled patients in the United States and Canada, while TETON-2 recruited outside those countries. Both were randomized, double-blind and placebo-controlled registration studies evaluating nebulized Tyvaso over 52 weeks, with absolute change in forced vital capacity as the primary endpoint. Eligible patients could continue commonly used background IPF therapies, allowing the studies to assess whether inhaled treprostinil could provide additional benefit within contemporary treatment.
TETON-1 produced an approximately 130.1 mL treatment advantage in absolute FVC at week 52 and reduced the risk of clinical worsening by 33% versus placebo. Combined TETON-1 and TETON-2 data then demonstrated the 111.8 mL FVC advantage and statistical significance across most major secondary measures, including acute exacerbation risk, percent-predicted FVC, quality-of-life assessment and diffusion capacity. Overall survival trended in favor of Tyvaso but did not meet statistical significance at week 52.
Why could an inhaled prostacyclin affect lung fibrosis?
Treprostinil is a prostacyclin mimetic best known for its vascular effects in pulmonary hypertension, but United Therapeutics argues that its activity may extend across fibrotic, inflammatory and vascular pathways relevant to IPF. The rationale for TETON originally emerged after a post hoc analysis of the INCREASE trial in patients with pulmonary hypertension associated with interstitial lung disease suggested that inhaled Tyvaso was associated with improved FVC.
Rather than treating that observation as definitive, United Therapeutics built the dedicated TETON registration program to test the hypothesis prospectively in IPF. Two positive Phase 3 studies now give the company a much stronger basis for claiming that the FVC effect represents reproducible treatment activity rather than an incidental finding inside a pulmonary-hypertension trial.
How would Tyvaso differ from existing IPF treatments?
Current IPF treatment commonly includes oral antifibrotic medicines that can slow disease progression but are limited by tolerability and do not stop the disease entirely. An inhaled therapy would introduce a different route of administration and mechanism, potentially allowing treatment to be layered onto existing background therapy rather than necessarily replacing it.
The TETON studies are particularly relevant because patients could be broadly treated with background medicines, including nintedanib, pirfenidone or no antifibrotic therapy depending on their clinical circumstances. United Therapeutics reported benefit across background-treatment subgroups in TETON-1, supporting the possibility that Tyvaso could become part of combination management rather than a mutually exclusive alternative.
What safety issues already accompany Tyvaso?
Tyvaso is already an established medicine in pulmonary hypertension, so its core safety profile is better characterized than that of a completely novel IPF molecule. The label warns that pulmonary and systemic vasodilation can cause symptomatic hypotension, while inhibition of platelet aggregation can increase bleeding risk. Inhaled treprostinil can also provoke bronchospasm, particularly in patients with underlying airway hyperreactivity.
Frequently reported adverse reactions in prior pulmonary arterial hypertension experience include cough, headache, throat irritation, nausea and flushing. The FDA will now evaluate how the benefit-risk profile looks specifically in patients with IPF, who may be older and have substantial respiratory impairment alongside other medicines and comorbidities.
How big could the IPF population be for United Therapeutics?
United Therapeutics estimates at least 100,000 people are living with IPF in the United States. The disease usually appears after age 50 and progressively reduces the lung’s ability to transfer oxygen, potentially culminating in respiratory failure.
The commercial opportunity is particularly meaningful because Tyvaso already has manufacturing, distribution and prescribing infrastructure in pulmonary vascular disease. Expanding an existing medicine into a major fibrotic-lung indication can therefore be operationally different from launching an entirely new product, although United Therapeutics will still need to educate pulmonologists about a treatment role that goes beyond pulmonary hypertension.
What comes after the IPF filing?
The FDA’s late-April 2027 review target is now the principal regulatory milestone. United Therapeutics is also evaluating nebulized Tyvaso in progressive pulmonary fibrosis through TETON-PPF, where enrollment has already been completed.
That broader program could eventually determine whether the medicine’s antifibrotic signal extends beyond idiopathic pulmonary fibrosis into other progressive fibrotic interstitial lung diseases. For now, the IPF application provides the clearest test: two Phase 3 studies produced a consistent FVC-preservation signal, and the FDA must decide whether that evidence supports turning a pulmonary-hypertension medicine into a new form of inhaled antifibrotic therapy.
